GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » EBIT

MBCOF (Marvel Biosciences) EBIT : $-0.53 Mil (TTM As of Oct. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Marvel Biosciences EBIT?

Marvel Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Oct. 2024 was $-0.18 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Oct. 2024 was $-0.53 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Marvel Biosciences's annualized ROC % for the quarter that ended in Oct. 2024 was %. Marvel Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Marvel Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Oct. 2024 was -9.39%.

Marvel Biosciences EBIT Historical Data

The historical data trend for Marvel Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences EBIT Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24
EBIT
-0.71 -0.88 -1.97 -1.71 -

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.36 -0.16 -0.20 - -0.18

Competitive Comparison of Marvel Biosciences's EBIT

For the Biotechnology subindustry, Marvel Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marvel Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's EV-to-EBIT falls into.


Marvel Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences  (OTCPK:MBCOF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Marvel Biosciences's annualized ROC % for the quarter that ended in Oct. 2024 is calculated as:

ROC % (Q: Oct. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jul. 2024 ) + Invested Capital (Q: Oct. 2024 ))/ count )
=-0.676 * ( 1 - 0% )/( (-1.1102230246252E-16 + -1.1102230246252E-16)/ 2 )
=-0.676/-1.1102230246252E-16
= %

where

Invested Capital(Q: Jul. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.358 - 1.172 - ( 0.252 - max(0, 1.172 - 0.358+0.252))
=-1.1102230246252E-16

Invested Capital(Q: Oct. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.166 - 1.164 - ( 0.06 - max(0, 1.164 - 0.166+0.06))
=-1.1102230246252E-16

Note: The Operating Income data used here is four times the quarterly (Oct. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Marvel Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Oct. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jul. 2024  Q: Oct. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.704/( ( (0 + max(-1.151, 0)) + (0 + max(-1.149, 0)) )/ 2 )
=-0.704/( ( 0 + 0 )/ 2 )
=-0.704/0
= %

where Working Capital is:

Working Capital(Q: Jul. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.021) - (1.172 + 0 + 0)
=-1.151

Working Capital(Q: Oct. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.015) - (1.164 + 0 + 0)
=-1.149

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Oct. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Marvel Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Oct. 2024 )
=-0.531/5.656
=-9.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences EBIT Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » EBIT
Comparable Companies
TSXV:IBO XCNQ:ASEP XCNQ:LOBE TSXV:IOT XCNQ:RIZE TSXV:XRTX TSX:APLI XCNQ:MBIO TSXV:QPT XCNQ:BLAB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
MRVL:Canada
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Website
https://www.marvelbiotechnology.com
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.